Revenue and profit declined sharply in H1 2024, with Bio-Chemical driving nearly all sales and profit. R&D intensity remains high, and the company is expanding production capacity amid robust global demand for nucleosides and specialty chemicals.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.